メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非アルコール性脂肪性肝炎治療薬市場 - 世界の業界分析、規模、シェア、成長、動向および将来予測

Nonalcoholic Steatohepatitis Therapeutics Market (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025

発行 Transparency Market Research 商品コード 357891
出版日 ページ情報 英文 65 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.89円で換算しております。
Back to Top
非アルコール性脂肪性肝炎治療薬市場 - 世界の業界分析、規模、シェア、成長、動向および将来予測 Nonalcoholic Steatohepatitis Therapeutics Market (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025
出版日: 2016年04月15日 ページ情報: 英文 65 Pages
概要

非アルコール性脂肪肝疾患は、アルコールをほとんどあるいは全く摂取しない人の肝臓の過剰な脂肪と特徴づけられる疾患で、直接的原因が特定されていません。しかし肥満やインスリン耐性が大きく関与していると考えられています。

当レポートでは、世界の非アルコール性脂肪性肝炎治療薬市場について調査し、市場の現状と将来見通し、薬剤別、地域別動向、および参入企業のプロファイルをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 非アルコール性脂肪性肝炎治療薬市場

  • イントロダクション
  • 非アルコール性脂肪性肝炎の疫学
    • 北米
    • 欧州
    • アジア太平洋地域
    • その他
  • 診断と治療
  • 市場動向
    • 阻害因子
    • 市場の機会

第4章 薬剤別市場

  • 概要
  • 第3相における潜在的薬剤候補
    • Obeticholic Acid(OCA)
    • Aramchol
    • Saroglitazar
    • Elafibranor
  • パイプライン分析
  • 地域別標的人口

第5章 提言

第6章 企業プロファイル

  • AstraZeneca plc
  • Intercept Pharmaceuticals Inc.
  • Galmed Pharmaceuticals
  • GENFIT SA
  • Gilead Sciences Inc.
  • Zydus Cadila
  • Immuron Ltd.
  • Conatus Pharmaceuticals
  • Tobira Therapeutics Inc.
  • その他
目次

Nonalcoholic fatty liver disease (NAFLD) is a disorder categorized by excess fat in the liver of people who drink little to no alcohol. No direct cause has yet been identified, however obesity and insulin resistance are believed to have major roles. Most often, NAFLD goes relatively undetected, as a liver can remain fatty without obstructing its function. Though, NAFLD can progress into a far more severe condition known as nonalcoholic steatohepatitis (NASH), a disease characterized by inflammation and irreversible cell death. NASH is a disease that advances over time. Over a period of ten years up to 20% of patients with NASH develop cirrhosis of the liver, and 10% die from the disease. At present, NASH is one of the leading causes of liver transplants in the U.S., with a considerable proportion of the general population currently suffering from the disease. NAFLD and NASH are both closely related to diabetes and obesity, and together are now considered as the leading cause of liver disease in Western countries. Thus, there is an urgent need for effective treatment options for these diseases. The need for treatment is expected to propel the growth of NASH therapeutics in coming years.

The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report provides a list of the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market followed by Obeticholic Acid (OCA) market and the market for Elafibranor is expected to grow at the highest CAGR.

The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes epidemiology of Nonalcoholic steatohepatitis (NASH) by region, to provide a thorough analysis of the overall addressable global market for the NASH therapeutics. Moreover, the report provides qualitative information about diagnosis and treatment of NASH.

The report also provides important recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the NASH market across different regions worldwide. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments.

Major players in this market are Astazeneca Plc (U.K.), Intercept Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd. (Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.), Zydus Cadila (India), Immuron Ltd. (Australia), Conatus Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.).

The Nonalcoholic Steatohepatitis (NASH) Therapeutics market has been segmented as follows:

Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type

  • Overview
  • Potential Drug Candidates in Phase III
  • Obeticholic Acid (OCA)
  • Aramchol (arachidyl amido cholanoic acid)
  • Saroglitazar
  • Elafibranor

Table of Contents

Chapter 1 - Introduction

  • 1.1. Report Description
  • 1.2. Research Methodology
  • 1.3. Market Segmentation
  • 1.4. Assumptions

Chapter 2 - Executive Summary

  • 2.1. Global NASH Market, by Drug, 2025(US$ Mn)

Chapter 3 - Global Nonalcoholic Steatohepatitis(NASH) Therapeutics Market Overview

  • 3.1. Introduction
  • 3.2. Epidemiology of Nonalcoholic Steatohepatitis(Qualitative Analysis)
    • 3.2.1. North America
    • 3.2.2. Europe
    • 3.2.3. Asia Pacific
    • 3.2.4. Rest of World
  • 3.3. Diagnosis and Treatment of NASH(Qualitative Analysis)
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

Chapter 4 - Global Nonalcoholic Steatohepatitis(NASH) Therapeutics Market, By Drug Type, 2015-2025(US$ Mn)

  • 4.1. Overview
  • 4.2. Potential Drug Candidates in Phase III
    • 4.2.1. Obeticholic Acid(OCA)
    • 4.2.2. Aramchol(arachidyl amido cholanoic acid)
    • 4.2.3. Saroglitazar
    • 4.2.4. Elafibranor
  • 4.3. Pipeline Analysis
    • 4.3.1. Tabular Representation of Phase I and Phase II Clinical Trials(Qualitative Analysis)
  • 4.4. Target Population By Geography: NASH Market

Chapter 5 Recommendations

Chapter 6 Company Profiles

  • 6.1. AstraZeneca plc
    • 6.1.1. Company Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Product Pipeline
    • 6.1.4. Business Strategies
    • 6.1.5. Recent Developments
  • 6.2. Intercept Pharmaceuticals Inc.
  • 6.3. Galmed Pharmaceuticals
  • 6.4. GENFIT SA
  • 6.5. Gilead Sciences Inc.
  • 6.6. Zydus Cadila
  • 6.7. Immuron Ltd.
  • 6.8. Conatus Pharmaceuticals
  • 6.9. Tobira Therapeutics Inc.
  • 6.10. Others
Back to Top